← SynDRA
ALECTINIB
SynDRA canonical compound SYN0026649 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | ALK inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- RET
- MET
- ABCG2
- EPHA1
- ROS1
- PHKG2
- KDR
- GAK
- FER
- EML4
- ACOX1
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- RET INHIBITOR
- Tyrosine-protein kinase receptor RET inhibitor
- EML4 INHIBITOR
- MET INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- DRD1
- EGFR
- PGR
- ESR1
- DRD3
- SRPK2
- NTRK1
- NR1I2
- SLC6A4
- ABCB11
- PDE3A
- HTR2B
- ADORA3
- PAK2
- OPRD1
- PAICS
- PAK4
- OPRM1
- AAK1
- OPA1
- PAK6
- NUAK2
- NR3C1
- NQO2
- NLK
- NEK9
- OLA1
- PDE4A
- PASK
- PCYT1A
- PPARG
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ALECENSA
- Alecensa
- alectinib hydrochloride
- alecensa
- CH5424802
- alectinib HCl
- RO5424802
- RO-5424802
- AF-802
- AF802
- ALECTINIB (CH5424802)
- Alectinib hydrochloride
- ALECTINIBCH-5424802CH5424802CT-CH542
- CH-5424802
- RG-7853
- RG-7853,CH5424802
- RG7853
- CH 5424802
- AF 802
- UNII-LIJ4CT1Z3Y
- LIJ4CT1Z3Y
- Alectinib (CH5424802)
- CHEMBL1738797
- AK170451
- C30H34N4O2
- 9-ethyl-6,6-dimethyl-
- CH5424802(Alectinib)
- ARQ-761
- Alectinib [INN]
- Alectinib [USAN:INN]
- Alectinib free base
- EMH
- ALECTINIB [MI]
- Alectinib (USAN/INN)
- ALECTINIB [USAN]
- ALECTINIB [WHO-DD]
- ch 5424802, Alectinib
- MLS006010971
Reported adverse events
- Bradycardia
- Constipation
- Dysgeusia
- Hepatotoxicity
- Myalgia
- Nausea
- Rash
- Vomiting
- Abdominal pain
- Back pain
- Cough
- Fatigue
Look up ALECTINIB in the interactive SynDRA portal →